title: Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study.
abstract: OBJECTIVE
  Using the technique of recursive partitioning and amalgamation analysis with verification, the Pediatric Oncology Group (POG) investigated the independent prognostic significance of previously published prognostic factors significantly associated with event-free survival (EFS) in B-progenitor cell acute lymphoblastic leukemia (ALL).
  
  
  METHODS
  Age, leukocyte count, sex, immunophenotype (expression of cytoplasmic immunoglobulin [Ig] and of surface antigens CD10 and CD34), and DNA index (ratio of the flow cytometry-determined DNA content of leukemia cells to that of normal diploid cells) were the variables used in the evaluation of four antimetabolite-based chemotherapy regimens in 1,535 children with the newly diagnosed B-progenitor cell ALL between February 1986 and May 1990.
  
  
  RESULTS
  There were three subgroups at widely different risks of treatment failure. A DNA index greater than 1.16 was the most prognostic feature. The final prognostic subgrouping was as follows: (1) DNA index greater than 1.16; (2) DNA index less than or equal to 1.16, age less than 11.0 years, and leukocyte count less than 50 x 10(9)/L; and (3) DNA index less than or equal to 1.16, (age greater than 11.0 years, and/or leukocyte count greater than 50 x 10(9)/L). These groups made up 20%, 53%, and 27% of the patients and had 4-year EFS rates (SE) of 90.1% (6.3%), 80.5% (5.1%), and 50.4% (7.6%), respectively.
  
  
  CONCLUSIONS
  Use of the DNA index, leukocyte count, and age--data that are relatively inexpensive and simple to obtain--may be sufficient to stratify patients with B-progenitor cell ALL for risk-directed therapy. Patients at an extremely low risk of failing therapy (approximately 20% of cases in this study) can thus be identified and spared the toxic short-term and late effects of more intensive therapies that may be needed for children with less favorable clinical and biologic features.
authors.affiliation: Department of Pediatrics, University of Kansas, Kansas City.
authors.forename: R
authors.initials: R
authors.lastname: Trueworthy
authors.forename: J
authors.initials: J
authors.lastname: Shuster
authors.forename: T
authors.initials: T
authors.lastname: Look
authors.forename: W
authors.initials: W
authors.lastname: Crist
authors.forename: M
authors.initials: M
authors.lastname: Borowitz
authors.forename: A
authors.initials: A
authors.lastname: Carroll
authors.forename: L
authors.initials: L
authors.lastname: Frankel
authors.forename: M
authors.initials: M
authors.lastname: Harris
authors.forename: H
authors.initials: H
authors.lastname: Wagner
authors.forename: M
authors.initials: M
authors.lastname: Haggard
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000502:physiology*; D002051:Burkitt Lymphoma / Q000235:genetics / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D004273:DNA, Neoplasm / Q000032:analysis; D006801:Humans; D007223:Infant; D007958:Leukocyte Count; D014411:Neoplastic Stem Cells; D011003:Ploidies; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000628:therapy*; D012044:Regression Analysis; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D004273:DNA, Neoplasm